![](https://monteverdelaw.com/wp-content/uploads/case-logo/adaptimmune-therapeutics-plc.png)
Adaptimmune Therapeutics plc (NASDAQ: ADAP), relating to its proposed merger with TCR² Therapeutics Inc. Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.
Adaptimmune Therapeutics plc (NASDAQ: ADAP), relating to its proposed merger with TCR² Therapeutics Inc. Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.